… cell lines. Although EGFR and AKT are constitutively phosphorylated in H3255, H1666, and
H441 cell lines, AKT is completely inhibited by gefitinib treatment only in the H3255 cell line. …

… in persons with lung cancer. Many of the principles of management relevant to gefitinib are
distinct … practical guidelines on the use of gefitinib in patients with non–small-cell lung cancer. …

… present study demonstrated that combined gefitinib treatment did not exhibit a synergistic
effect on the autophagy and apoptosis induced in lung cancer cells following the inactivation of …

… of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor
mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer …

… Thus, gefitinib may also inhibit tumor growth by interfering … , gefitinib treatment alters
expression levels of key molecules in tumor cells that are important for stimulating proliferation, cell …

… studies of gefitinib therapy in patients with advanced non–small-cell lung cancer and
EGFR … We then undertook a phase 3 study comparing gefitinib and standard carboplatin–paclitaxel …

… in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic
factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res …

… of the EGFR gene in patients with gefitinib-sensitive lung cancer, as compared with none of
… lung cancer showed potential for identifying patients who would respond to gefitinib therapy…

… lung cancer samples from US patients who responded to gefitinib therapy and in a lung
adenocarcinoma cell … inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. …

… gefitinib has shown potent activity in a number of tumor models, including several lung cancer
cell … 2) in pretreated non-small cell lung cancer reported a response rate approaching 20% …